Telavancin: a novel lipoglycopeptide for serious Gram-positive infections

Bibliography

• RICE LB: Antimicrobial resistance in Gram-positive bacteria. Am. J. Med. (2006) 119(6A):S11-S19.
   PubMedGoogle Scholar
• DERYKE CA, MAGLIO D, NICOLAU DP: Defining the need for new antimicrobials: clinical and economic implications of resistance in the hospitalized patient. Expert Opin. Pharmacother. (2005) 6(6):873-889.
   PubMed Web of Science ®Google Scholar
• SCHMIDT-IOANAS M, ROUX A, LODE H: New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient. Curr. Opin. Crit. Care (2005) 11:481-486.
   PubMed Web of Science ®Google Scholar
• LEE SY, FAN HW, KUTI JL, NICOLAU DP: Update on daptomycin: the first approved lipopeptide antibiotic. Expert Opin. Pharmacother. (2006) 7(10):1381-1397.
   PubMedGoogle Scholar
• MORAN GJ, KRISHNADASAN A, GORWITZ RJ et al.: Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. (2006) 355:666-674.
   PubMed Web of Science ®Google Scholar
• BAMBEKE FV: Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr. Opin. Pharmacol. (2004) 4(5):471-478.
   PubMed Web of Science ®Google Scholar
• BOSSO JA: The antimicrobial armamentarium: evaluating current and future treatment options. Pharmacotherapy (2005) 25(10):55S-62S.
   PubMed Web of Science ®Google Scholar
• SILVERMAN JA, MORTIN LI, VANPRAAGH AD, LI T, ALDER J: Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J. Infect. Dis. (2005) 191(12):2149-2152.
   PubMed Web of Science ®Google Scholar
• PACE JL, JUDICE JK: Telavancin (Theravance). Curr. Opin. Investig. Drugs (2005) 6(2):216-225.
   PubMedGoogle Scholar
• BEAUREGARD DA, WILLIAMS DH, GWYNN MN, KNOWLES DJ: Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob. Agents Chemother. (1995) 39(3):781-785.
   PubMed Web of Science ®Google Scholar
• LEADBETTER MR, ADAMS SM, BAZZINI B et al.: Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J. Antibiot. (Tokyo) (2004) 57(5):326-336.
   PubMed Web of Science ®Google Scholar
• JUDICE JK, PACE JL: Semi-synthetic glycopeptide antibacterials. Bioorg. Med. Chem. Lett. (2003) 13(23):4165-4168.
   PubMed Web of Science ®Google Scholar
• HIGGINS DL, CHANG R, DEBABOV DV et al.: Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (2005) 49(3):1127-1134.
   PubMed Web of Science ®Google Scholar
• CHEN L, WALKER D, SUN B, HU Y, WALKER S, KAHNE D: Vancomycin analogues active against vanA-resistant strains inhibit bacterial transglycosylase without binding substrate. Proc. Natl. Acad. Sci. USA (2003) 100(10):5658-5663.
   PubMed Web of Science ®Google Scholar
• PACE JL, YANG G: Glycopeptides: update on an old successful antibiotic class. Biochem. Pharmacol. (2006) 71(7):968-980.
   PubMed Web of Science ®Google Scholar
• DRAGHI DC, JONES M, THORNSBERRY C, FLAMM RK, SAHM DF: Telavancin activity against current and diverse Staphylococcus aureus populations. 45th ICAAC. Washington DC, USA (16 – 19 December 2005):177 (Poster).
   Google Scholar
• JANSEN WTM, VEREL A, FLEER A, VERHOEF J, MILATOVIC D: In vitro susceptibility of clinical bacterial isolates to telavancin. 16th European Congress of Clinical Microbiology and Infectious Diseases. Nice, France (1 – 4 April 2006):1401 (Poster).
   Google Scholar
• BRAUERS J, KRESKEN M, BAGEL S: Comparative in vitro activities of telavancin and other antibacterial agents against selected Gram-positive bacteria. 16th European Congress of Clinical Microbiology and Infectious Diseases. Nice, France (1 – 4 April 2006):1582 (Poster).
   Google Scholar
• KING A, PHILLIPS I, KANIGA K: Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J. Antimicrob. Chemother. (2004) 53:797-803.
   PubMed Web of Science ®Google Scholar
• LEUTHNER KD, CHEUNG CM, RYBAK MJ: Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. (2006) 58:338-343.
   PubMed Web of Science ®Google Scholar
• GANDER S, KINNAIRD A, FINCH R: Telavancin: in vitro activity against staphylococci in a biofilm model. J. Antimicrob. Chemother. (2005) 56:337-343.
   PubMed Web of Science ®Google Scholar
• DRAGHI DC, JONES M, THORNSBERRY C, FLAMM RK, SAHM DF: Telavancin activity against current and diverse populations of enterococci and Streptococcus pneumoniae. 45th ICAAC, Washington DC, USA (16 – 19 December 2005):180 (Poster).
   Google Scholar
• KRAUSE K, JOHNSTON D, WU T et al.: Comparative in vitro susceptibility and bactericidal activity of TD-6424 against Streptococcus pneumoniae and non-pneumococcal streptococci from the United States and Europe. 43rd ICAAC. Chicago, USA (14 – 17 September 2003):CI-1634 (Poster).
   Google Scholar
• GOLDSTEIN EJ, CITRON DM, MERRIAM CV, WARREN YA, TYRRELL KL, FERNANDEZ HT: In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic Gram-positive species and Corynebacterium spp. Antimicrob. Agents Chemother. (2004) 48(6):2149-2152.
   PubMed Web of Science ®Google Scholar
• KRAUSE K, DEBABOV D, PACE J, KANIGA K: Low frequency of spontaneous resistance to TD-6424 and delayed resistance selection in vitro among staphylococci and enterococci. 43rd ICAAC. Chicago, USA (14 – 17 September 2003):CI-1810 (Poster).
   Google Scholar
• KRAUSE KM, BENTON BM, HIGGINS DL, KANIGA K, RENELLI M, HUMPHREY P: Telavancin (TLV) possesses low potential for resistant mutant selection in serial passage studies of Staphylococcus aureus and enterococci. 15th European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, Denmark (2 – 5 April 2005):1577 (Poster).
   Google Scholar
• SHAW JP, SEROOGY J, KANIGA K, HIGGINS DL, KITT M, BARRIERE S: Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. (2005) 49(1):195-201.
   PubMed Web of Science ®Google Scholar
• SUN HK, DUCHIN K, NIGHTINGALE CH, SHAW JP, SEROOGY J, NICOLAU DP: Tissue penetration of telavancin after intravenous administration in health subjects. Antimicrob. Agents Chemother. (2006) 50(2):788-790.
   PubMed Web of Science ®Google Scholar
• LODISE TP, GOTFRIED M, BARRIERE S, DRUSANO GL: Telavancin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. 43rd Infectious Disease Society of America. San Francisco, USA (6 – 9 October 2005):526 (Poster).
   Google Scholar
• GOTFRIED M, DUCHIN K, SHAW JP et al.: Telavancin penetrates well into human pulmonary epithelial lining fluid and alveolar macrophages and is unaffected by pulmonary surfactant. 45th ICAAC. Washington DC, USA (16 – 19 December 2005):A-14 (Poster).
   Google Scholar
• SMITH PF, TSUJI BT, KELCHIN P, OKUSANYA OO, FORREST A: Effects of human serum on in vitro activity of telavancin. 46th ICAAC. San Francisco, USA (27 – 30 September 2006):A-0659 (Poster).
   Google Scholar
• DUCHIN K, SHAW J, SPENCER E, SEROOGY J, BARRIERE S, WILBRAHAM D: Single dose pharmacokinetics (PK) of telavancin (TLV) in subjects with renal dysfunction. 14th European Congress of Clinical Microbiology and Infectious Diseases. Prague, Czech Republic (1 – 4 May 2004):P1028 (Poster).
   Google Scholar
• DUCHIN K, SHAW JP, SEROOGY J, BARRIERE S, NOVACK R: Effect of hemodialysis on single dose pharmacokinetics (PK) of telavancin (TLV). 15th European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, Denmark (2 – 5 April 2005):P897 (Poster).
   Google Scholar
• PATEL JH, GRIO M, CHURCHWELL MD, SEROOGY JD, BARRIERE S, MUELLER BA: Telavancin transmembrane clearance during in vitro continuous venovenous hemofiltration (CVVH). 16th European Congress of Clinical Microbiology and Infectious Diseases. Nice, France (1 – 4 April 2006):1538 (Poster).
   Google Scholar
• PATEL JH, GRIO M, CHURCHWELL MD, SEROOGY JD, BARRIERE S, MUELLER BA: Telavancin pharmacokinetics during in vitro continuous venovenous hemodialysis (CVVHD). 16th European Congress of Clinical Microbiology and Infectious Diseases. Nice, France (1 – 4 April 2006):1539 (Poster).
   Google Scholar
• DUCHIN K, SHAW J, SPENCER E, SEROOGY J, BARRIERE S, WILBRAHAM D: Single dose pharmacokinetics (PK) of telavancin (TLV) in healthy elderly subjects. 14th European Congress of Clinical Microbiology and Infectious Diseases. Prague, Czech Republic (1 – 4 May 2004):P1027 (Poster).
   Google Scholar
• PACE JL, KRAUSE K, JOHNSTON D et al.: In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob. Agents Chemother. (2003) 47(11):3602-3604.
   PubMed Web of Science ®Google Scholar
• BARCIA-MACAY M, MINGEOT-LECLERCQ MP, TULKENS PM, BAMBEKE FV: Telavancin accumulates in cultured macrophages and is active against intracellular S. aureus. 45th ICAAC. Washington, DC, USA (16 – 19 December 2005):A-1831 (Poster).
   Google Scholar
• BARCIA-MACAY M, LEMAIRE S, MINGEOT-LECLERCQ MP, TULKENS PM, BAMBEKE FV: Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. (2006) 58:1177-1184.
   PubMed Web of Science ®Google Scholar
• HEGDE SS, REYES N, WIENS T et al.: Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria. Antimicrob. Agents Chemother. (2004) 48(8):3043-3050.
   PubMed Web of Science ®Google Scholar
• LUBENKO I, SMIRNOVA MV, STRUKOVA E, VOSTROV S, ZINNER S, FIRSOV A: Anti-staphylococcal effects of telavancin in an in vitro dynamic model: impact of different half-lives and initial concentrations. 16th European Congress of Clinical Microbiology and Infectious Diseases. Nice, France (1 – 4 April 2006):1519 (Poster).
   Google Scholar
• MADRIGAL AG, BASUINO L, CHAMBERS HF: Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. (2005) 49(8):3163-3165.
   PubMed Web of Science ®Google Scholar
• MIRO JM, MARCO F, GARCIA DE LA MARIA C et al.: Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediately susceptible Staphylococcus aureus (GISA). 16th European Congress of Clinical Microbiology and Infectious Diseases. Nice, France (1 – 4 April 2006):1158 (Poster).
   Google Scholar
• REYES N, SKINNER R, KANIGA K et al.: Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (2005) 49(10):4344-4346.
   PubMed Web of Science ®Google Scholar
• STUCKI A, GERBER P, ACOSTA F, COTTAGNOUD M, COTTAGNOUD P: Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters. Antimicrob. Agents Chemother. (2006) 50(2):770-773.
   PubMed Web of Science ®Google Scholar
• HEGDE S, REYES N, BENTON B, SKINNER R: Telavancin is more efficacious than vancomycin in a murine model of bacteremic peritonitis induced by methicillin-resistant Staphylococcus aureus. 16th European Congress of Clinical Microbiology and Infectious Diseases. Nice, France (1 – 4 April 2006):1543 (Poster).
   Google Scholar
• REYES N, SKINNER R, BENTON BM et al.: Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. (2006) 58:462-465.
   PubMed Web of Science ®Google Scholar
• STRYJEWSKI ME, O’RIORDAN WD, LAU WK et al.: Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria. Clin. Infect. Dis. (2005) 40:1601-1607.
   PubMed Web of Science ®Google Scholar
• STRYJEWSKI ME, CHU VH, O’RIORDAN WD et al.: Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob. Agents Chemother. (2006) 50(3):862-867.
   PubMed Web of Science ®Google Scholar
• COREY R, STRYJEWSKI M, O’RIORDAN W et al.: Telavancin for the treatment of complicated skin and skin structure infections (cSSSI): results of the ATLAS I study. 44th Infectious Disease Society of America. Toronto, Canada (12 – 15 October 2006):LB-17 (Poster).
   Google Scholar
• BARRIERE S, GENTER F, SPENCER E, KITT M, HOELSCHER D, MORGANROTH J: Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J. Clin. Pharmacol. (2004) 44:689-695.
   PubMed Web of Science ®Google Scholar